Recipharm and Adroit Science form collaboration to expand service offering

Recipharm AB and Adroit Science AB today announce the formation of a new strategic collaboration.  Adroit Science AB will supportRecipharm's pharmaceutical development with high quality solid state characterisation services.  By combining expertise in formulation development, API development, chemical analysis and solid state characterisation, both the speed and cost of development can be reduced whilst, at the same time, quality is improved. 

"I am very excited about this collaboration", says Carl-Johan Spak, Executive Vice President, Development & Technology at Recipharm. "With the addition of development services from Adroit, we will have a very competitive offering, which will help our customers to progress their projects in a highly efficient way.  Adroit Science AB has fast established itself as one of the leading providers of solid state characterisation services in Northern Europe. Indeed, we can offer an even better service to our customers through this collaboration, including complete development from molecule to product."

"Adroit Science and Recipharm have already cooperated in a number of successful projects, and this formal partnership marks the logical next step in the mutual development of our strategic relationship. We are delighted to join forces with a leading CDMO like Recipharm and predict that this will bring new opportunities in worldwide customer support" remarked Hans Gredeby, CEO of Adroit Science AB.


Contact information
Carl-Johan Spak, EVP Development & Technology, [email protected]
+46 8 6025 313
Hans Gredeby, CEO Adroit Science AB, +46 46 2756 121

For media enquiries, please contact Tristan Jervis or Alex Heeley at De Facto Communications on: E-mail: [email protected] or [email protected]
Tel: +44 (0) 207 861 3019/3043


About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 2,200 employees.  Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material including API and pharmaceutical product development. Recipharm manufactures more than 400 different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm's turnover is approximately SEK 3.3 billion and the Company operates development and manufacturing facilities in Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered in Jordbro, Sweden. The RecipharmB-share (RECI B) is listed on NASDAQ Stockholm.  

For more information on Recipharm and our services, please visit www.recipharm.com        

About Adroit Science AB
Adroit Science Sweden, is an expert company dedicated to the exploration and characterization of substances and formulations. From our modern lab at Medicon Village in Lund we provide advanced laboratory and consultancy services to the pharmaceutical industry with focus on solid state characterization and understanding. The company was started in 2012 and our customers include the full range from small innovator to major top-10 pharma companies as well as drug substance manufacturers.

More information can be found on our website www.adroitscience.com

Suggested Articles

Dubbed “Project Nightingale,” the efforts were announced amid concerns and federal inquiries into the data’s safekeeping and patient consent for use.

Independent site management organization Panthera Biopartners has kick-started its first clinical trial in the U.K.

WIRB-Copernicus Group’s clinical services division bought out trial consultancy firm Waife & Associates as it looks to boost its management services.